Back to top
more

IDEXX Laboratories (IDXX)

(Delayed Data from NSDQ)

$476.27 USD

476.27
490,369

+2.99 (0.63%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $476.27 0.00 (0.00%) 7:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Hologic's Panther Fusion Flu A/B/RSV Assay Gets FDA Approval

Hologic's (HOLX) receipt of FDA approval for Panther Fusion Flu A/B/RSV assay running on the new Panther Fusion system is likely to boost its Diagnostic segment.

    PerkinElmer Hits a 52-Week High: What's Driving the Stock?

    PerkinElmer's (PKI) portfolio has not only boosted the company's organic growth trajectory but has also helped boost market share worldwide. Solid estimate revision trend boosts investor confidence.

      Masimo (MASI) Launches Trace Data and Reporting Tool in US

      Masimo's (MASI) launch of Trace in the United States will aid the company in capturing the growing patient data visualization market.

        Genomic Health's Cost Pressure Mounts, Cancer Tests Strong

        Concerns related to Genomic Health's (GHDX) strong dependence on breast cancer tests still linger. Also, higher production cost and expenses continue to weigh heavily on the company's margins.

          Integra Rides High on Product Launches, Competition Rife

          Integra LifeSciences' (IART) latest launch of new sizes of SurgiMend and PriMatrix and Omnigraft as well as continued growth in private label products is encouraging.

            Henry Schein to Offer CAS' Fully-Automated Cognivue Device

            Henry Schein (HSIC) is consistently working toward boosting its Medical segment.

              Hill-Rom (HRC) Rides on Product Launches, Competition Rife

              Hill-Rom (HRC) focuses on product innovation through research and development. Its product launches slated for the fourth quarter are boosting investors' confidence.

                Integra LifeSciences' SurgiMend PRS Meshed Boosts ADM Line

                Advancing its portfolio of acellular dermal tissue matrix for plastic and reconstructive surgery, including breast reconstruction, Integra LifeSciences (IART) launched SurgiMend PRS Meshed in Europe.

                  AmerisourceBergen's PharMEDium Slows Down, Competition Rife

                  AmerisourceBergen'S (ABC) growth story is expected to be stunted by tepid performance at PharMEDium. Also steep competition is a cause of concern.

                    AngioDynamicis' (ANGO) Solero MTA System to Drive Growth

                    Growth in the core Angiographic Catheter business is also likely to fortify the company's footprint in the global space.

                      Integra Closes Codman Buyout, Strengthens Neurosurgery Arm

                      With Codman's acquisition by Integra (IART), the neurosurgery business is likely to drive the company's 2018 adjusted earnings per share with a minimum yield of 22 cents.

                        Amedisys' Arm Buys Intercity Home Care, Boosts U.S. Base

                        Amedisys' (AMED) encouraging efforts put the Personal Care business on growth track. This segment lives up to a strong performance with the integration of several recent tuck-in acquisitions.

                          Boston Scientific's Apama Deal to Boost Electrophysiology Arm

                          Boston Scientific's (BSX) Apama Medical addition is expected to strengthen its suite of arrhythmia solutions under the Electrophysiology sub-segment.

                            Quest Diagnostics Buys 2 Outreach Labs, Widens Customer Base

                            Quest Diagnostics (DGX) completes acquisition of outreach laboratory services of two Hartford HealthCare hospitals. The deal is expected to widen the network of the company.

                              Abbott to Gain from Alere's Takeover Due for Oct 3 Closure

                              Alere's acquisition would help Abbott (ABT) explore new channels and geographies, including forays into fast growing outlets like doctors' offices, clinics, pharmacies and at-home testing.

                                AngioDynamics (ANGO) Misses on Earnings & Revenues in Q1

                                AngioDynamics' (ANGO) adjusted gross margin decreased year over year owing to voluntary market withdrawal of the Acculis Microwave Tissue Ablation System.

                                  Masimo RAS-45 Full-Market Release to Boost Respiratory Care

                                  Masimo Corporation's (MASI) newly launched RAS-45, a single use adhesive respiration sensor would strengthen the company's foothold in the growing global respiratory care market.

                                    Baxter Announces Launch of DeviceVue System for Sigma Pumps

                                    Baxter's (BAX) latest development is expected to fortify its foothold in the smart pumps market.

                                      Here's Why Mazor Robotics (MZOR) Stock Is Worth a Bet Now

                                      The market is upbeat about Mazor Robotics' (MZOR) recent CE Mark approval for Mazor X Surgical Assurance platform.

                                        STERIS (STE) Rides on Organic Growth, Stiff Contest a Threat

                                        STERIS' (STE) consistent strong organic all-segment growth performance impresses investors. Additionally, growth in free cash flow reserve denotes the company's solid cash position.

                                          Here's Why You Should Invest in Orthofix International Now

                                          Orthofix (OFIX) rides high on strength in Biologics and Spine Fixation.

                                            Allscripts Rides High on Product Launches Amid Rising Costs

                                            Management at Allscripts Healthcare (MDRX) is focused on various restructuring initiatives, research and development plans and launch of exclusive products.

                                              Omnicell (OMCL) Gains on Product Launches, Global Expansion

                                              The market is upbeat about Omnicell's (OMCL) recently-launched XT Series Automated Supply Dispensing Cabinet. The company is also expanding its footprint globally.

                                                Align Technology (ALGN) Prospects Bright, Competition Rife

                                                Align Technology (ALGN) continues to gain from strong InvisAlign sales amid macroeconomic headwinds.

                                                  Cerner (CERN) Banks on RCM & PH Platforms, Competition Rife

                                                  Cerner's (CERN) stable position provides solid growth opportunities in the revenue cycle management (RCM) suite of solutions.